1E
11.5.2021 16:37:09 CEST | Business Wire | Press release
1E , innovators in endpoint management, today announced Unified eXperience Management (UXM) , a new category that seeks to address the siloed approach inherent in tools in the Digital Experience Monitoring (DEM) space.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005842/en/
Due to the relative immaturity of the Digital Experience Management category, most tooling is focused on identifying and reporting on the scale of the problem, scoring, and issue identification. These tools create analytics silos that give insight, but are uncoupled from the automation technology that can actually improve end-user experience at an enterprise scale. Meanwhile, employees are becoming increasingly more frustrated, with 56% feeling dissatisfied with their IT experience . Organizations looking to improve the digital experience of all their employees need to move beyond analytics and embrace automation to resolve these issues.
Furthermore, this siloed approach of today’s DEM solutions neglects the substantial investment most large organizations have made into platforms like ServiceNow and Microsoft. The industry needs a solution that can leverage these investments to be part of the solution rather than ignore them.
1E is introducing the UXM category in response to these issues that unifies Digital Experience Monitoring with all the other aspects of IT required to positively impact the user’s experience. Unified eXperience Management comprises Experience Monitoring, Employee Engagement, Diagnostic and Remediation tooling, and Configuration Policy to ensure that once an issue is fixed on one machine it is applied to all machines on an ongoing basis. Deep and rich integration with service desk and UEM platforms like ServiceNow and Microsoft Endpoint Manager enable IT workers dealing with incidents to have access to insights and a shared library of fixes to ensure that end-user issues are dealt with in real-time.
“If a Digital Experience initiative can identify experience issues but has no clear line of sight to remediating them, it will deliver zero value; No employee ever wished IT had a better analytics solution,” said Sumir Karayi, CEO and founder of 1E. “They want less frustrating experiences, they want fewer disruptions. For this, IT needs to take a step beyond analytics that identifies issues, to an initiative that leverages automation to predict and improve experiences. That is how we view Unified eXperience Management -- proactive, real time, holistic action across all endpoints.”
To accompany the launch of the category, 1E’s Product Chief Technologist, Bogdan Udrea, will host a webinar exploring UXM and how it can help organizations enable a modern, hybrid workplace on May 18 at 11 a.m. ET. To attend, please visit: https://info.1e.com/webinar-go-beyond-digital-experience-management-what-is-uxm
This coincides with the latest release of 1E Tachyon , which brings new UXM capabilities to market. Tachyon 5.2 contains a unified device view that expedites troubleshooting and remediation of an endpoint on a single pane of glass. The latest release also introduces a new persona management capability, allowing IT to better understand the needs and experience challenges of different cohorts of employees.
Product Marketing Director, Michael Wright, will be launching Tachyon 5.2 on May 20th at 11am ET. To attend the launch event, please visit: https://info.1e.com/launch-showcase-tachyon-5.2-discover-complete-device-visibility
WFA Research: https://www.1e.com/wfa-research-2021/
About 1E
1E the innovators in endpoint management that supports the work from anywhere enterprise, so employees are secure, supported, and productive wherever they want to be. The 1E Tachyon Platform provides real-time diagnosis, remediation and automation that fixes issues, fast and without interruption. It puts employees in control, through self-service, self-heal and sentiment monitoring to understand how they really feel and reduces help desk calls and ultimately costs. That’s why more than 1,700 organizations in 42 countries trust 1E to help them manage 14 million endpoints seamlessly. For more information, visit www.1E.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005842/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom